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ABSTRACT
Breast cancer stem cells (CSCs) are considered as the root of mammary 
tumorigenesis. Previous studies have demonstrated that ISL efficiently limited the 
activities of breast CSCs. However, the cancer prevention activities of ISL and its 
precise molecular mechanisms remain largely unknown. Here, we report a novel 
function of ISL as a natural demethylation agent targeting WIF1 to prevent breast 
cancer. ISL administration suppressed in vivo breast cancer initiation and progression, 
accompanied by reduced CSC-like populations. A global gene expression profile assay 
further identified WIF1 as the main response gene of ISL treatment, accompanied 
by the simultaneous downregulation of β-catenin signaling and G0/G1 phase arrest 
in breast CSCs. In addition, WIF1 inhibition significantly relieved the CSC-limiting 
effects of ISL and methylation analysis further revealed that ISL enhanced WIF1 
gene expression via promoting the demethylation of its promoter, which was closely 
correlated with the inhibition of DNMT1 methyltransferase. Molecular docking analysis 
finally revealed that ISL could stably dock into the catalytic domain of DNMT1. Taken 
together, our findings not only provide preclinical evidence to demonstrate the use of 
ISL as a dietary supplement to inhibit mammary carcinogenesis but also shed novel 
light on WIF1 as an epigenetic target for breast cancer prevention.
INTRODUCTION
With the advancements of early-detection systems 
and multidisciplinary treatments, the 5-year survival ratio 
of breast cancer has been greatly improved. However, 
breast cancer incidence has risen sharply since 2008 by 
more than 20% worldwide, and 1.7 million women were 
diagnosed with breast cancer in 2012 globally [1]. The 
development of preventive biomarkers and targeting 
agents with high safety for breast cancer has become an 
urgent issue worldwide.
In the past decade, the discovery of CSCs in various 
types of cancer has challenged our traditional view of 
cancer incidence. For breast cancer, Al-hajj et al. [2] 
initially identified breast CSCs with CD44+/CD24−/low  
markers in 2003. Breast CSCs were characterized as 
having strong abilities of self-renewal, tumorigenesis 
and high metastasis [3]. As few as 100 breast CSCs could 
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form tumors when injected into non-obese diabetic/severe 
combined immunodeficiency disease (NOD/SCID) mice, 
and CSCs were also identified to be a critical initiator for 
the formation of a metastasis lesion [4]. Targeting aberrant 
signaling pathways in breast CSCs has become a novel 
approach to effectively prevent breast cancer.
Recent studies indicate that the Wnt/β-catenin 
signaling pathway plays a critical role in mediating 
bioactivities of CSCs, including mammosphere formation 
capability, differentiation potential and tumorigenesis 
ability [5]. Compared with the Notch and Hedgehog 
pathways, the Wnt/β-catenin pathway has been strongly 
implicated in mammary development and tumorigenesis 
since the discovery of Wnt1 as a mammary oncogene by 
viral insertion in mouse mammary tumors in the 1980s 
[6]. In particular, MMTV-Wnt1 transgenic mice display 
alveolar hyperplasia early in life, and nearly 100% of these 
animals ultimately develop focal mammary carcinomas 
[7]. In addition, other Wnt family members including 
Wnt2, Wnt9a, Wnt7b, and Wnt10b were found to be 
aberrantly upregulated in human breast cancer tissues 
when compared with normal mammary tissues [8]. 
Meanwhile, the high expression of cytoplasmic and/or 
nuclear β-catenin was found to be closely correlated with 
breast cancer prognosis [10], and nuclear β-catenin could 
interact with the lymphocyte enhancer factor/T cell factor 
family of transcription factors (LEF/TCF) to activate 
multiple cancer-related molecules, including c-Myc, 
cyclin D1, metalloproteinases and c-Met, etc. [11–13]. In 
addition, Wnt/β-catenin signaling could also be abnormally 
stimulated by oncogenic mutations of several critical 
components within this pathway, such as APC, Axin and 
TCF4, etc. [9]. However, mutations in such key regulators 
were not frequently observed in human breast cancer 
patients, indicating possible alternative mechanisms for the 
hyperactivation of the Wnt/β-catenin signaling pathway.
The epigenetic silencing of multiple secreted 
Wnt antagonists is a strikingly common event in 
breast cancer, although the causal relationship between 
their loss-of-expression and mammary carcinogenesis is 
less well established. There generally exist two classes of 
secreted Wnt antagonists, defined by their mechanisms of 
action. The first class encompasses the Dkk family proteins, 
which internalize the Wnt co-receptors LRP5/6 via 
endocytosis to suppress downstream signaling transduction. 
Another class includes Wnt inhibitory factor 1 (WIF1), the 
sFRP family and Cerberus, which exert inhibitory effects 
by directly binding to the Wnt ligands [14–15]. Compared 
to other suppressors, WIF1 inactivation is a common 
event in breast cancer. Both studies by Ai et al. [16] and 
Veeck et al. [17] revealed that WIF1 downregulation by 
hypermethylation was detected in more than 60% of human 
breast carcinoma samples. Furthermore, WIF1 is expressed 
at high levels in human normal breast cells and mammary 
tissues, suggesting that WIF1 elevation would possibly 
maintain normal mammary development while attenuating 
mammary tumorigenesis [18].
Dietary compounds have attracted growing interest 
for use in cancer chemoprevention and are advantageous 
owing to their wide availability, low toxicity and high 
tolerability [19]. Currently, multiple natural dietary 
compounds are potent in inhibiting breast cancer growth 
and limiting breast CSCs, such as epigallocatechin-
3-gallate (EGCG), resveratrol, and piperine [20–22]. 
However, their role in breast cancer prevention and 
the underlying molecular mechanisms remain largely 
unknown. Isoliquiritigenin (ISL), a chalcone-type dietary 
compound derived from licorice root and many other 
plants, possesses anti-cancer activities possibly via 
proliferation reduction, cell cycle arrest, angiogenesis 
suppression, metastasis inhibition and apoptosis 
induction [23–27]. In addition, its chemopreventive 
role in breast cancer has been reported recently. ISL 
suppressed phorbol ester-induced cyclooxygenase-2 
(COX-2) expression in the non-tumorigenic MCF-10A 
breast cell line and was capable of inhibiting DMBA-
induced mammary carcinogenesis in rats [28–39]. Our 
pilot results demonstrated that ISL could directly target 
GRP78 to chemosensitize breast CSCs via β-catenin/
ABCG2 signaling [13]. Although it was found that 
ISL limited breast CSCs via increased proteasomal 
degradation of β-catenin, the effects of ISL on breast 
cancer chemoprevention and its underlying mechanisms 
on Wnt/β-catenin signaling deserve further investigation.
In this study, we utilized the mouse mammary tumor 
virus promoter-driven polyoma middle T oncoprotein 
(MMTV-PyMT) transgenic mouse model to demonstrate 
the breast cancer chemoprevention effects of ISL exposure. 
It was determined that ISL administration suppressed 
in vivo breast cancer initiation and progression and was 
accompanied by a reduced CSC-like population. Microarray 
analysis further revealed that WIF1 is the main response 
gene of ISL, accompanied by limited mammosphere 
formation ability and G0/G1 phase arrest of breast CSCs. 
Notably, DNA methylation analysis demonstrated that ISL 
significantly demethylated the promoter region of WIF1 
and inhibited the expression of DNMT1 methyltransferase. 
Molecular docking analysis revealed that ISL could 
stably dock into the catalytic domain of DNMT1, thus 
competitively reversing the WIF1 methylation status. Taken 
together, our findings discovered a novel function of ISL 
as a natural DNMT1 inhibitor to prevent breast cancer by 
targeting the aberrant WIF1 signaling.
RESULTS
ISL suppresses mammary hyperplasia and 
breast cancer initiation in vivo
We initially evaluated the chemopreventive effects 
of ISL on breast cancer in the MMTV-PyMT mice. 
This mouse model produces spontaneous and luminal-
like breast cancer from normal mammary epithelium 
and can recapitulate similar pathological processes and 
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characteristics found in human breast cancer. In particular, 
mammary hyperplasia can be detected in this model as 
early as 4 weeks of age, and nearly 100% of mice develop 
breast cancer by 12–15 weeks, accompanied by the 
appearance of pulmonary metastasis [30–31]. Therefore, 
it is an internationally well-accepted preclinical model for 
investigating the mechanisms of mammary carcinogenesis 
and chemopreventive effects of natural phytochemicals.
ISL (50 mg/kg/d) and vehicle were administered to 
mice by oral gavage everyday according to the schedule 
illustrated in Figure 1A. The cancer prevention activity of 
ISL was initially assessed by comparing the incidence of 
palpable lesions at different time intervals in the transgenic 
mice of each group. As shown in Figure 1B, ISL treatment 
obviously delayed the onset of palpable lesions. The 
cancer progression was also significantly slowed down by 
ISL intervention when compared with the vehicle group. 
In particular, the median time to a 50% cancer-burden in 
the glands was 8 weeks in the vehicle group, while it was 
10 weeks in the ISL-treated group. By the 12th week, all 
mammary glands (n = 100) were identified as breast cancer 
in the vehicle group, while more than 10 glands were 
free of lesions in the ISL treatment group. Meanwhile, 
the mean tumor volume from the 4th to 12th weeks in the 
ISL intervention group was also significantly decreased 
compared with the vehicle group, as presented in Figure 1C.
To further investigate the effects of ISL on breast 
tumor initiation, the abdominal mammary glands of mice 
were harvested for whole mount preparation at varying 
stages. At 4 weeks after birth, only a rudimental primary 
duct and a small number of branches can be observed in 
wild-type mice (Figure 1Di). As the mice age, the length 
of ducts, the amount of duct branches, and the number 
of terminal ends gradually grow in wild-type mice 
(Figure 1Dj-l). Alternatively, in MMTV-PyMT transgenic 
mice, hyperplastic lesions could be observed as early 
as the 4th week around duct branches, while no lesions 
were detected in the ISL treatment group at the same age 
(Figure 1De). As the mice grew older, the transgenic mice 
gave rise to increasing numbers of mammary tumors, 
while ISL treatment significantly limited tumor foci 
growth and dispersion (Figure 1Dc,g).
Hematoxylin and eosin (H&E) staining further 
showed the effects of ISL on the cellular morphology of 
mouse mammary glands at varying stages. As shown in 
Figure 1E, the 4-week-old vehicle group began to develop 
hyperplastic lesions, which presented as multiple foci 
around the ducts. The cellular morphology of an ISL-
treated gland was similar to that of wild type, and almost 
no premalignant lesions were found. In the 6th week of 
age, hyperplastic lesions were present in the mammary 
glands of the control and ISL-treated groups. However, 
ISL treatment markedly decreased the malignant cell 
proliferation within the acini and ducts when compared 
with the control group in the 9th week. With tumor 
progression to the 12th week, individual tumor acini began 
to merge in the control group, while no such feature was 
found in the ISL-treated group. Immunohistochemical 
analysis also showed that ISL treatment could decrease 
Ki67 expression in the tumor tissues at varying stages, 
indicating the proliferation speed of tumor cells was 
remarkably inhibited by ISL (Figure 1F). Collectively, 
ISL significantly prevented mammary cancer occurrence 
and growth in the MMTV-PyMT transgenic mouse model.
ISL treatment inhibits breast cancer growth and 
lung metastasis in vivo
Accumulating evidence has suggested that 
MMTV-PyMT mice could develop well-differentiated, 
luminal-type mammary adenomas with lung metastasis 
lesions in or after the 10th week [32]. Therefore, we further 
examined the effects of ISL on breast cancer growth and 
metastasis at the 13th week, the endpoint of our experiment. 
As shown in Figure 2A, mammary tumors from the 
vehicle group displayed a more necrotic and hemorrhagic 
appearance than ISL-treated tumors, while no obvious 
visual differences in the pulmonary specimens were 
observed between the two groups. H&E analysis further 
indicated that tumors from both groups showed almost 
the same features of malignancy, including solid sheets 
of malignant cells, marked cell morphology variation, 
obvious nuclear atypia and the loss of the basement 
membrane. Meanwhile, several metastatic nodules were 
present in the lung parenchyma of the control group, while 
few such lesions were visible in the ISL-treated group. 
Although ISL treatment did not result in obvious changes 
in the histopathology of the end-stage tumors based on 
H&E staining, it significantly inhibited the tumor volume 
and tumor burden. ISL elicited a dramatic decrease of 
658 mm3 in the mean tumor volume, and a significant 
18% reduction in the tumor burden compared to the vehicle 
groups (Figure 2B, 2C). The discrepancy in the mean 
number of metastatic nodules further revealed that ISL 
harbored the potential for limiting metastasis (Figure 2D). 
Kaplan-Meier curve analysis further demonstrated 
that ISL significantly prolonged the survival time of 
MMTV-PyMT mice, possibly owing to the decreased 
tumor burden and the limited lung metastasis (Figure 2E). 
Additionally, ISL had little effect on mouse body weight 
between the two groups, indicating that ISL might be 
developed as a chemoprevention agent with high safety 
(Supplementary Figure 1).
Identification of WIF1 by microarray profiling 
as the primary target of ISL in limiting 
breast CSC
Accumulating evidence has suggested that cancer 
is a stem cell disorder. These rare CSCs are possibly the 
ultimate roots of tumorigenesis, tumor recurrence and 
metastasis [33]. To investigate the effects of ISL on the 
origination of breast CSCs, we harvested primary cells from 
the spontaneous mammary tumors of MMTV-PyMT mice 
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for flow cytometry analysis. Two independent markers for 
breast CSCs were applied. First, a Hoechst 33342-based 
“side population” (SP) assay was utilized for detecting the 
effects of ISL on the CSC population. ISL treatment reduced 
the cancer stem-like cell proportion from 15.7 ± 1.23 to 
2.36 ± 0.24 (Figure 3A). Aldehyde dehydrogenase (ALDH) 
was then applied as another marker for detection of stem-
like cells and a specific inhibitor diethylaminobenzaldehude 
(DEAB) against ALDH was used as a negative control to 
minimize the influence of background fluorescence [34]. 
Compared with the DEAB negative control, tumors from 
untreated mice consisted of approximately 2% ALDHhi cells, 
while ISL administration dramatically decreased ALDHhi 
cells to 0.4% (Figure 3B). Both results indicated that ISL 
might prevent breast cancer occurrence and development via 
limiting breast CSCs.
Microarray analysis was then applied to identify 
genes that could be affected by ISL. The candidate gene 
profiles of MMTV-PyMT tumors with or without ISL were 
determined by identification of genes with expression 
changes at least 2.0-fold and with a P value less than 0.05. 
As indicated in Figure 3C, a total number of 249 genes 
were finally selected, among which 132 genes were 
up-regulated, and 117 genes were down-regulated. 
Meanwhile, 14 genes were found that were involved in 
CSC activities and categorized into functional clusters that 
included Wnt/β-catenin signaling, Hedgehog signaling and 
other CSC-related genes. Then, a real-time PCR assay 
was used to validate the results of the microarray analysis. 
As shown in the right panel of Figure 3D, the decreased 
expression of Smad7, Bmp2, Klf4, Abca12, Abca9, Car4, 
Fzd4, Nkd1, Nkd2, Ptch2 and Shh and the up-regulation 
of Axin2, WIF1 and Dkk1 were all validated. Meanwhile, 
it was revealed that WIF1 was the gene with the highest 
expression alteration by ISL among the 14 candidate genes 
(Figure 3D).
Figure 1: ISL inhibited mammary carcinogenesis in MMTV-PyMT transgenic mice. A. Schematic illustration of ISL 
administration. Mice were randomly divided into vehicle and ISL treatment groups, and ISL was given by oral gavage at 50 mg/kg/d 
from the 3rd to the 12th week (n = 10 mice, total of 100 glands); B. Tumor incidence ratios between the vehicle and ISL treatment groups 
were compared using a log-rank test. The results revealed that ISL significantly inhibited breast cancer occurrence (P < 0.001); C. Tumor 
volumes of each group were measured from the 4th to the 12th weeks. Tumor volume was calculated based on ex vivo caliper measurements 
of individual tumors using the formula V = (W2× L)/2, where V is tumor volume, W is tumor width, and L is tumor length. The results 
indicated that ISL significantly inhibited tumor growth (*P < 0.05, **P < 0.01, values represented as the Mean ± SD, n = 10). D. Whole 
mount staining of abdominal mammary glands of mice from the 4th to 12th weeks in the wild type, vehicle, and ISL intervention groups;  
E. Representative H&E staining images of mouse mammary glands from the 4th to the 12th weeks in the wild type, vehicle, and ISL 
intervention groups. F. Representative immunohistochemical images of Ki 67 staining in mouse mammary glands from the 4th to the 
12th weeks in the wild type, vehicle, and ISL intervention groups.
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Figure 2: ISL inhibited breast cancer growth and lung metastasis in MMTV-PyMT transgenic mice. A. Representative 
images of tumors and lungs dissected from vehicle or ISL-treated mice. H&E staining was utilized to observe tumor micromorphology of 
each group with 400 fold magnification; B. Scatter plot of individual tumors and the mean tumor volume (red line) and the SEM derived 
from mice tumors at the end of ISL treatment (50 mg/kg/d); C. Mean tumor burden per mouse at the experimental endpoint, analyzed by 
Student’s t test. Tumor burden per mouse was calculated as tumor weight per body weight (*P < 0.05, values represented as the mean ± SD, 
n = 10); D. Mean metastatic nodule count in each group at the experimental endpoint was compared (***P < 0.001, values represented as 
the mean ± SD, n = 10); E. Mouse survival in the vehicle and ISL intervention groups is shown by the Kaplan-Meier curve.
To further examine the relevance of WIF1 to 
the chemopreventive effects of ISL, the mRNA levels 
of WIF1 in mammary tissues from vehicle and ISL-
treated groups were examined by RT-PCR. The results 
revealed a significant elevation of WIF1 by ISL treatment 
when compared to the vehicle control (Figure 4A). In 
addition, western blot analysis also confirmed that ISL 
administration led to an increase in WIF1 expression 
levels as time progressed from the 4th to the 12th week 
(Figure 4B). Furthermore, immunohistochemistry staining 
showed that WIF1 was expressed in wild-type mammary 
tissues in mice from weanlings to adults (Figure 4C). 
However, WIF1 expression was significantly attenuated in 
MMTV-PyMT mice, particularly after tumor development. 
Notably, augmentation of WIF1 expression was observed 
in ISL-treated mammary tissues, especially when the 
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hyperplasia had developed to the carcinoma stage at 
the 12th week of age. Additionally, the distribution of 
WIF1 positive cells at the hyperplasic stage (4–6 weeks) 
was quite different from that at the carcinoma stage 
(12 weeks); specifically, WIF1 localization changed from 
primarily the outer layer of lesions to being distributed 
throughout the entire tumor.
ISL limits the self-renewal ability of human 
breast CSCs in vitro
After in vivo examination, the classic “stem-like” 
phenotype of CD44+CD24−/low was applied to determine 
the effects of ISL on the MDA-MB-231 triple-negative 
breast cancer cell line and the MCF-7 luminal cancer 
cell line. Flow cytometry results showed that ISL could 
significantly limit the population of breast CSCs in both 
cell lines (Figure 5A). In particular, 25 μM ISL eliminated 
the CD44+CD24−/low population of MDA-MB-231 cells 
by 23%, whereas 50 μM ISL resulted in over a 37% 
reduction of CSC-like cells. Similar findings were also 
obtained in MCF-7 cells. Compared to 6.64% of breast 
CSCs in the untreated MCF-7 cells, the proportion of 
CD44+CD24−/low cells dropped to 3.52% and 2.92% after 
treatment with 25 and 50 μM ISL for 24 h, respectively. 
ALDH was also applied for detection of stem-like cells 
with or without ISL plus the specific inhibitor DEAB. It 
was shown that ISL at 50 μM could reduce ALDH factions 
from 4.97% to 1.41% in MDA-MB-231 and from 1.24% 
to 0.298% in MCF-7, indicating that ISL could suppress 
the ALDHhi population in both cell lines (Figure 5B). The 
results suggested ISL could decrease CSC populations 
characterized with either ALDHhi or CD44+CD24−/low 
markers.
To study the effects of ISL on the self-renewal 
ability of breast CSCs, we further sorted breast CSCs 
from MDA-MB-231 and MCF-7 cells and performed a 
mammosphere formation assay. As shown in Figure 5C, 
Figure 3: Identification of WIF1 as the main target of ISL by microarray profiling. A. Representative SP analysis using 
primary mouse mammary cells freshly harvested from the spontaneous mammary tumors of vehicle or ISL-treated MMTV-PyMT mice. 
The SP (the framed area) was shown as a percentage of the viable cell population and analyzed by FlowJo software; B. The ALDEFLUOR 
assay was then used to determine the population of CSCs in the spontaneous mammary tumors of vehicle or ISL-treated MMTV-PyMT 
mice. An ALDH-specific inhibitor DEAB was used as a negative control for minimizing background fluorescence. ALDHhi cells were 
shown as cells residing in the framed area analyzed by FlowJo software; C. Affymetrix Mouse Gene 2.0 ST GeneChip was utilized  
to reveal the gene expression changes after ISL treatment in MMTV-PyMT mice. Through GeneSpring12.6 analysis, 132 genes were 
upregulated, whereas 117 genes were downregulated; D. 14 genes including Smad7, Bmp2, Klf4, Abca12, Abca9, Ca4, Fzd4, Nkd1, Nkd2, 
Ptch2, Shh, Axin2, WIF1 and Dkk1 were identified as CSC-related genes affected by ISL. Real-time PCR analysis was then applied to 
validate their expression changes and WIF1 was finally determined as the main response gene of ISL.
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Figure 4: ISL significantly elevated WIF1 expression in MMTV-PyMT mice. A. Real-time PCR analysis revealed that ISL 
significantly increased WIF1 mRNA expression in mammary tumors of MMTV-PyMT mice at the end of the experiment; B-C. Western 
blotting and immunohistochemistry analysis further confirmed that ISL gradually increased WIF1 expression from the 4th to the 12th week.
untreated MDA-MB-231 CSCs could be enriched in 
non-adherent spherical clusters of cells. However, ISL 
treatment significantly inhibited the formation of primary 
spheres. Compared to the control group, the number of 
spheres at 1st passage declined to 63.7% and the size 
of mammospheres was also inhibited to 42.2% after 
addition of 25 μM ISL. Additionally, the limited self-
renewal ability of ISL-treated cells was also evident in the 
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secondary and tertiary propagation of breast CSCs. Similar 
inhibitory effects of ISL were observed in the breast CSCs 
that were sorted from MCF-7 cells.
Because it was reported that WIF1 expression might 
be correlated with cell cycle progression, we studied the 
effect of ISL on the cell cycle distribution of breast CSCs. 
In the sorted MDA-MB-231 CSCs, 25 μM ISL could 
arrest cell cycle at the G0/G1 phase after 24 h (78.22% 
of ISL-treated cells versus 61.81% of untreated cells) 
and 48 h treatment (84.09% of ISL-treated cells versus 
66.19% of untreated cells). Similar inhibitory activities 
of ISL on the G0/G1 population were obtained in the 
MCF-7 CSCs. The proportion of ISL-treated CSCs in 
G0/G1 phase increased from 57.87% to 78.23% after 
24 h, and continued to elevate from 67.39% to 81.57% 
after 48 h. These results suggested that ISL might limit the 
self-renewal ability of breast CSCs via cell cycle arrest at 
G0/G1 phase (Figure 5D).
ISL inhibits Wnt/β-catenin signaling in a WIF1 
dependent manner
After validating the effects of ISL on limiting breast 
CSCs, we continued to examine whether ISL could exert 
stimulatory effects on WIF1 in breast cancer cell lines. 
As illustrated in Figure 6A, both breast cancer cell lines 
treated with ISL showed dose-dependent elevations of 
WIF1 transcript levels. However, it was observed that 
WIF1 mRNA expression reached the highest point at 
24 h of treatment and then gradually decreased after 
prolonged culture in both cell populations, suggesting that 
the WIF1 gene expression might be correlated with cell 
cycle progression, consistent with the findings of Liu et al 
[35]. To further evaluate the endogenous protein levels of 
WIF1 in the presence or absence of ISL, WIF1 expression 
was further examined by western blot (Figure 6B) and 
immunofluorescent staining (Figure 6C). Both results 
(Continued )
Figure 5: ISL limited the self-renewal ability of breast CSCs. A. Representative dot plots of CD44+CD24−/low cell surface markers 
in MDA-MB-231 and MCF-7 cells using the BD FACSAria SORP cell sorter. Breast cancer cells were incubated with 25 or 50 μM ISL for 
24 h. CD44-FITC and CD24-PE antibodies were utilized to frame CSC-like subsets in the lower right quadrant (Q3). The isotype-matched 
antibody served as a negative control. The data analysis was performed using FlowJo software (*P < 0.05, **P < 0.01, values represented 
as the mean ± SD, n = 3). The results suggested that ISL administration significantly reduced the CSCs population in both cancer cells in a  
dose-dependent manner; B. The ALDEFLUOR assay was then used to determine the population of CSCs in MDA-MB-231 and MCF-7 
cells after ISL administration. The ALDH-specific inhibitor DEAB was used as a negative control for minimizing background fluorescence. 
ALDHhi cells were shown as cells residing in the framed area analyzed by FlowJo software; time-dependent manner in both CSCs.
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Figure 5 (Continued ): C. Effects of ISL on the primary, secondary and tertiary mammospheres formed by the sorted CSCs from 
MDA-MB-231 and MCF-7 cells. The CSCs were incubated with or without ISL (10, 25 or 50 μM) for 7 days. The number and size of 
the mammospheres were determined using fluorescence microscopy (*P < 0.05, **P < 0.01, ***P < 0.001 vs. negative control of the 1st 
passage spheres; *P < 0.05, **P < 0.01, ***P < 0.001 vs. negative control of the 2nd passage spheres; ^P < 0.05, ^^P < 0.01, ^^^P < 0.001 
vs. negative control of the 3rd passage spheres, values represented as the mean ± SD, n = 3); the results showed that ISL administration  
could significantly limit the number and size of mammospheres formed by both CSCs populations; D. The effects of ISL on cell cycle 
distributions of the sorted CSCs from MDA-MB-231 and MCF-7 cells. The CSCs were incubated with or without 25 μM ISL at 24 h and 
48 h and then subjected to cell cycle investigation analyzed by Modifit LT software. The results indicated that ISL arrested cell cycle at G0/
G1 phase in a time-dependent manner in both CSCs.
revealed that ISL could stimulate WIF1 expression in both 
breast cancer cell lines.
Because Wnt/β-catenin signaling is closely 
correlated with the self-renewal ability of breast CSCs, 
we therefore determined the inhibitory effects of ISL on 
β-catenin expression in MDA-MB-231 cells. As shown 
in Figure 7A, ISL inhibited both cytosolic and nuclear 
β-catenin expression in a time- and dose-dependent 
manner but without great influences on its mRNA 
expression. Meanwhile, a series of genes downstream 
of β-catenin, including Cyclin D1, C-Myc, Survivin 
and Oct-4, were also simultaneously suppressed by 
ISL, indicating that the down-regulation of β-catenin 
might occur at the post-translational level (Figure 7B). 
To elucidate whether the enhanced WIF1 expression 
is critical for inducing the down-regulated β-catenin 
expression by ISL, we cultured breast CSCs in ISL-
treated conditional medium (CM) of MDA-MB-231 cells, 
and a WIF1 neutralizing antibody was added to the culture 
system to see whether WIF1 inhibition would relieve the 
CSC-limiting effects of ISL. Western blotting results 
showed that when compared to the negative control, 
ISL CM significantly inhibited β-catenin expression 
via phosphorylating β-catenin and dephosphorylating 
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GSK-3β. However, the expression of β-catenin was 
elevated by 24% and 65% after adding WIF1 neutralizing 
antibody to the culture system at 2 μg/ml and 4 μg/ml, 
respectively (Figure 7C). Meanwhile, flow cytometry 
results also demonstrated that WIF1 inhibition could 
reverse the down-regulation of breast CSCs induced 
by ISL in MDA-MB-231 breast cancer cells, but an 
isotype-matched IgG at 4 μg/ml did not (Figure 7D). 
On the other hand, mammosphere results showed that 
ISL CM could significantly limit the number and size 
of the mammospheres compared to the negative control, 
while the number and size of the primary mammospheres 
were increased to 1.3- and 2.4-fold, respectively, by 
adding anti-WIF1 antibody at 2 μg/ml, and to 2.1- and 
3.6-fold, respectively, at 4 μg/ml, but not by an isotype-
matched IgG (Figure 7E). These results indicated that 
ISL inhibited the Wnt/β-catenin signaling in a WIF1-
dependent manner.
ISL elevates WIF1 expression by promoter 
demethylation through inhibiting DNMT1
Accumulating evidence has supported that low 
levels of WIF1 in breast cancer were largely attributed 
to its aberrant hypermethylation [16]. To further unravel 
the potential mechanisms underlying the stimulatory 
effects of ISL on WIF1 expression, we next investigated 
whether ISL would suppress WIF1 promoter methylation 
in breast cancer cells. An MSP primer set (WIF1 MSP-F 
and WIF1 MSP-R) and BGS primer set (WIF1 BGS-F 
and WIF1 BGS-R) were designed to target the WIF1 
promoter region. When MSP analysis was used on 
bisulfite-modified genomic DNA harvested from the 
untreated MDA-MB-231 and MCF-7 cells, we observed 
strong amplification with the methylation-specific primers, 
indicating a high CpG methylation status within the WIF1 
promoter. In contrast, ISL administration led to WIF1 
Figure 6: ISL resulted in overexpression of WIF1 levels in human breast cancer cell lines. Breast cancer cells were treated 
with the indicated concentrations of ISL for different times and collected for A. Real-time PCR and B. western blotting analysis. The 
results indicated that following ISL treatment, WIF1 expression in both cancer cell lines reached the maximum level at 24 h and then 
began to decrease with time increasing; C. The distribution of WIF1 in MDA-MB-231 and MCF-7 cells after ISL treatment was studied 
by immunofluorescence analysis. The nuclei were counterstained by DAPI. Fluorescent images were obtained using a Carl Zeiss LSM710 
META laser scanning confocal microscope and were analyzed with ZEN software.
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Figure 7: ISL inhibited breast CSCs in a WIF1-dependent manner. A. MDA-MB-231 cells treated with ISL at varying 
concentrations or time intervals were assayed by western blotting for β-catenin (cytoplasmic and nuclear) and ALDH1A3 antigen. β-actin 
and Lamin B were used as cytoplasmic and nuclear protein loading controls, respectively. The results indicated that ISL administration 
inhibits ALDH1A3 and β-catenin expression in a dose-and time-dependent manner; B. The relative β-catenin mRNA levels and the 
transcriptional activities of its downstream genes before and after ISL treatment in MDA-MB-231 were determined by real-time PCR 
analysis. (*P < 0.05, **P < 0.01, ***P < 0.001, values represented as the mean ± SD, n = 3); C. Breast CSCs of MDA-MB-231 were 
cultured in ISL-treated CM, and 2 or 4 μg/ml WIF1 neutralizing antibody was added to the culture system. Western blotting results revealed 
that WIF1 inhibition relieved the β-catenin-inhibitory effects of ISL, accompanied by the reactivation of Cyclin D1 and the phosphorylation 
of GSK-3β and AKT; D. WIF1 inhibition reversed the inhibitory effects of ISL on CSC populations in MDA-MB-231 cells; E. WIF1 
inhibition abrogated the inhibitory effects of ISL on the mammosphere formation ability of CSCs. Breast CSCs were cultured in ISL-treated 
CM, and WIF1 neutralizing antibody was added to the culture system at 2 or 4 μg/ml. The number and size of the primary and secondary 
mammospheres were determined using fluorescence microscopy after 7 days (*P < 0.05, **P < 0.01 vs. negative control of the 1st passage 
spheres, *P < 0.05, **P < 0.01 vs. negative control of the 2nd passage spheres, values represented as the mean ± SD, n = 3).
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promoter demethylation in a dose- and time-dependent 
manner, presenting as decreased amplification with 
methylation-specific primers and increased amplification 
with unmethylated-specific primers (Figure 8A).
To confirm our MSP results and determine how ISL 
affects WIF1 promoter methylation in breast cancer, we 
used bisulfite sequencing to analyze the methylation status 
of 39 CpG sites within the 415-bp fragment of the WIF1 
promoter (from − 555 to − 140) in MDA-MB-231 and 
MCF-7 cells (Figure 8B). Consistent with the MSP results, 
we found that these CpG islands were densely methylated 
in the detected sequences of both of the untreated cell lines, 
presenting as 88.2% methylated in MDA-MB-231 and 
50.3% methylated in MCF-7 cells. After ISL treatment, 
the methylation levels were significantly reduced (69.2% 
methylation in ISL-treated MDA-MB-231 cells, 39.5% 
methylation in ISL-treated MCF-7 cells). These results 
suggested that the enhanced WIF1 expression by ISL 
might largely correlate with reduced promoter methylation 
of this gene during breast tumorigenesis.
Elevated expression of DNA methyltransferases 
(DNMTs), mainly DNMT1 and DNMT3B, has been 
reported to be largely responsible for the aberrant 
WIF1 hypermethylation in breast tumors [16]. We thus 
continued to assess whether ISL could suppress the 
DNMTs to mediate the WIF1 demethylation effects 
of ISL. Both in vitro western blotting and in vivo 
IHC analysis revealed that ISL had little influence on 
DNMT3b, while it significantly inhibited DNMT1 protein 
expression (Figure 8C). These results suggested that 
the demethylation activity of ISL on WIF1 was mainly 
through the inhibition of DNMT1 rather than DNMT3b. 
The mRNA levels of DNMT1 were also decreased after 
ISL administration in vitro and in vivo (Figure 8D). In 
addition, DNMT1 silencing could assist ISL not only in 
elevating WIF1 expression but also in down-regulating 
β-catenin levels, implying that DNMT1 played a crucial 
role in mediating the chemoprevention effects of ISL 
(Left panel, Figure 8E). The specificity protein 1 (Sp1) is 
a zinc finger transcription factor that preferentially binds 
to GC-rich motifs of many promoters and is capable of 
transcriptionally regulating DNMT1 [35]. Herein, we 
found that ISL administration led to a significant reduction 
of Sp1 levels (Right panel, Figure 8E), indicating that 
ISL promoted WIF1 demethylation possibly through 
inactivating a Sp1/DNMT1-dependant pathway.
Figure 8: ISL elevated WIF1 expression by promoter demethylation through inhibiting DNMT1 expression. A. MSP 
analysis was conducted on bisulfite-modified genomic DNA harvested from MDA-MB-231 and MCF-7 in the presence or absence of 
ISL at varying concentrations. The results indicated that ISL significantly increased the expression of unmethylated WIF1 promoter DNA 
fragments; B. BGS analysis further confirmed that ISL significantly demethylated the promoter region of WIF1 in both breast cancer 
cells. For BGS lollipop-style representation, filled (black) circles correspond to methylated Cs, and unfilled (white) circles correspond to 
unmethylated Cs. Each row represents the sequencing results from a single clone. For BGS aggregated representation, each box corresponds 
to one CpG position in the genomic sequence. The colored bars summarize the methylation states of all sequences at that position;
(Continued )
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To further explore the binding mode of ISL with 
DNMT1 at the molecular level, we conducted a molecular 
docking analysis of ISL using a homology model 3SWR 
at the catalytic site of the DNMT1 crystal structure. Using 
Discovery studio software, we determined that ISL could 
stably be found at the C-terminal catalytic domain of the 
catalytic site of DNMT1. In particular, ISL could form 
stable hydrogen bonds with four active residues including 
GLU1168, GLU1266, ARG1312 and ASN1578. ISL 
could also form a strong π–π interactions with TRP1170, 
which were crucial to the catalytic mechanism of DNMT1 
(Figure 9).
DISCUSSION
Breast cancer is the second leading cause of death 
among US women, with 39, 620 recorded cancer deaths 
and 232, 340 new cases of invasive breast cancer in 
2013 [36]. The effective prevention of breast cancer 
has become a global task to further decrease its current 
incidence ratio and mortality [37–39]. The two major 
strategies to reduce breast cancer risks include (1) the 
avoidance of cancer-causing biological, chemical, and 
physical agents and (2) the habitual consumption of 
diets high in supplements that protect against cancer 
[40]. Chemoprevention, the second approach, involves 
the administration of one or more naturally occurring 
and/or synthetic agents that can prevent, delay, or even 
reverse the development of pre-malignant lesions by 
suppressing the multi-step carcinogenic process [41–42]. 
In clinical trials, breast cancer chemoprevention has 
mainly focused on endocrine intervention using selective 
estrogen receptor modulators (SERMs) and aromatase 
inhibitors (AIs). Unfortunately, these drugs are active in 
prevention of hormone responsive lesions only and have 
poor or no effect in reducing the risk of hormone receptor-
negative breast cancer [43–44]. Meanwhile, a number of 
side effects, such as endometrial cancer and osteoporosis, 
may be brought forth by SERMs or AIs. Therefore, the 
development of alternative chemopreventive agents is 
urgently necessary. Currently, dietary compounds are 
gaining increased attention for their plentiful resources, 
multi-target properties, excellent safety profiles and 
economic value when compared to conventional agents 
[45–46]. ISL, a representative dietary phenolic compound 
mainly derived from licorice, has been demonstrated 
to have potent inhibitory effects on breast cancer cell 
proliferation, particularly in the estrogen-negative breast 
cancer cell lines MDA-MB-231 and BT549 [13]. This 
suggests that ISL has potential to develop as an alter-
native and novel agent in breast cancer treatment and 
prevention. Our previous study revealed that it exhibited 
the greatest inhibitory effects on β-catenin transcription 
activity among ten types of phytochemical candidates, 
consequently resulting in its potent anti-cancer effects 
[13]. Its chemopreventive effects have also been reported 
recently. Tak et al. observed chemopreventive effects 
in the non-tumorigenic MCF-10A breast cell line [28]. 
Animal studies found protective effects of ISL against 
DMBA-induced mammary carcinogenesis, DMBA-
induced skin carcinogenesis and azoxy-methane-induced 
colon carcinogenesis [29, 47–48]. Nevertheless, limited 
studies have been undertaken to reveal the underlying 
mechanisms for ISL’s chemopreventive potential, 
particularly in mammary carcinogenesis.
Similar to the above findings, we also observed that 
ISL was capable of delaying mammary carcinogenesis 
and cancer metastasis in MMTV-PyMT transgenic 
mice, accompanied by a significant decrease in the CSC 
population. Microarray analysis using MMTV-PyMT 
Figure 8 (Continued ): C. Western blotting and immunohistochemistry analysis indicated that ISL significantly inhibited the level  
of DNMT1 expression rather than DNMT3b; D. DNMT1 mRNA levels in MDA-MB-231 cells and tumor tissues before and after ISL 
treatment were assessed by RT-PCR, and normalized to β-actin or GAPDH internal control. (*P < 0.05, **P < 0.01, values represented as 
the mean ± SD, n = 3); E. Left panel: DNMT1 siRNA administration further enhanced the stimulatory effects of ISL on WIF1 expression, 
indicating the critical role of DNMT1 in mediating the demethylation effects of ISL; Right panel: ISL inhibited the expression of SP1.
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tumors was conducted to unravel the underlying molecular 
mechanisms of ISL. The results suggested that the ISL 
chemopreventive effects might be tightly related to the 
significant WIF1 augment, which was closely correlated 
with the regulation of CSC self-renewal. Interestingly, 
WIF1 inhibition relieved the CSC-limiting effects of ISL, 
and it was found that ISL stimulated WIF1 expression 
by promoting its promoter demethylation. It has been 
reported that aberrant DNA methylation may be one of 
the earliest events contributing to carcinogenesis [49–50], 
and our data further demonstrated the central role of WIF1 
methylation in breast cancer development and prevention. 
Restoring WIF1 levels by modifying its DNA methylation 
patterns has been suggested as an anti-cancer strategy in 
other malignancies. Tang et al. [51] determined that WIF1 
could suppress tumor growth via G1 arrest in bladder 
cancer by the down-regulation of SKP2 and c-myc, as 
well as the up-regulation of p21/WAF1 and p27/Kip1. 
Rubin et al. [52] reported that elevated WIF1 decreased 
the risks of cancer metastasis in an osteosarcoma mouse 
model with attenuated expression of MMP-9 and MMP-14. 
Ramachandran et al. [53] found that WIF1 re-expression 
induced significant apoptosis and G2/M arrest, inhibiting 
cervical cancer cell proliferation in vitro and tumor growth 
in vivo. Most studies elevated WIF1 levels using the 
common DNA demethylating agent 5-azacytidine (5-Aza) 
and its derivative 5-aza-20-deoxycytidine (Decitabine), 
which have been tested in phase I and II trials for many 
forms of cancer. They have been demonstrated to have 
significant, although usually transient, improvement in 
patient survival [54–55]. However, these agents are largely 
limited due to their clinical toxicity. The major toxicity of 
these drugs is myelosuppression, and the most commonly 
reported nonhematologic adverse effect was nausea and 
vomiting, which was grade 3–4 in approximately 10% of 
patients [56–57]. Among metastatic lung cancer patients, 
the toxicity of decitabine occurred in a dose- and schedule-
dependent manner, which required a 5–6-week recovery 
period before the next cycle of therapy [58]. Alternatively, 
our study suggested using a dietary phytochemical ISL to 
reverse WIF hypermethylation and suppress mammary 
tumorigenesis. Previous studies revealed that the minimum 
lethal dose of ISL was not less than 3000 mg/kg (oral 
administration) or not less than 1000 mg/kg (intra-
peritoneal administration) in 5-week-old mice [59]. In our 
pilot studies, ISL oral administration posed little toxicity 
to normal tissues and mammary stem cells in mice, even 
with chronic administration at 100 mg/kg/d for 3 months, 
Figure 9: The molecular binding mode of ISL with the catalytic domain within DNMT1. It was predicted by the LigandFit 
algorithm in Discovery Studio 2.5 using the homology-docking template of 3SWR. It was found that ISL could form stable hydrogen 
bonds with four active residues including GLU1168, GLU1266, ARG1312 and ASN1578. Meanwhile, ISL could also form a strong π–π 
interaction with TRP1170. Blue dashed lines, hydrogen bonds; orange line, π–π interactions.
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making it desirable as a chemopreventive agent for breast 
cancer treatment [13]. Collectively, we demonstrated 
that the dietary compound ISL, at its safe dosages, 
could effectively reverse the epimutational events, thus 
suppressing a series of delayed premalignant progressions 
(including primary/advanced hyperplasia, adenoma) 
before the onset of mammary malignancy.
DNMTs have been revealed to be central mediators 
for the aberrant epigenetic regulation [60]. Here, we 
found that ISL restored WIF1 levels, likely by regulating 
the enzyme DNMT1, which preferentially methylates 
hemimethylated DNA over unmethylated DNA. Human 
DNMT1 is a protein with 1616 amino acids and its 
structure can be divided into an N-terminal regulatory 
domain and a C-terminal catalytic domain [61]. DNMT1 
disorder was considered to be a significant molecular 
event to induce carcinogenesis by transferring methyl 
group from S-adenosylmethionine (SAM) to the fifth 
position of the cytosine ring [60]. Targeting DNMT1 has 
become a promising strategy to prevent cancer occurrence. 
Nowadays, DNMT1 inhibitors could be divided into 
following categories: (1) trapping DNMT1 through 
DNA incorporation (such as decitabine, 5-azacytidine 
and zebularine); (2) blocking the catalytic active site of 
DNMT1 (such as sinefungin, epigallocatechin gallate 
(EGCG) and RG108); (3) interrupting the binding 
site between DNMT1 and DNA (such as procaine and 
procainamide); (4) inducing DNMT1 degradation (such as 
decitabine) and (5) suppressing DNMT1 expression (such 
as antisense MG-98) [62–63].
Based on our findings, ISL might act as both 
a transcriptional modulator and a chemical inhibitor 
of DNMT1. It was observed that ISL significantly 
decreased DNMT1 mRNA and protein expression 
levels, accompanied with decreased Sp1 levels. Sp1 is a 
zinc finger transcription factor that preferentially binds to 
GC-rich motifs of many promoters [64]. Numerous studies 
reported that SP1 was involved in multiple biological 
processes, including cell proliferation, cell growth, DNA 
damage and chromatin remodeling [16, 35, 64]. Clinical 
studies also indicated that Sp1 expression was aberrantly 
elevated in various types of cancer, and closely correlated 
to TNM classification, tumor invasion and lymph node 
metastasis [65]. With regard to breast cancer, elevated Sp1 
was found to regulate thousands of genes that are critically 
involved in mammary tumorigenesis and metastatic 
progression, such as vascular endothelial growth factor, 
urokinase plasminogen activator and its receptor, cyclin 
D1 and BRCA1 [66]. Recently, Sp1 was also discovered 
as a transcriptional regulator of DNMT1 [67]. Meanwhile, 
it was found that Sp1 binding site (5′-GGCGGG-3′) was 
also exited in the promoter region of WIF1 [68]. Since Sp1 
was able to recruit DNMT1 and other methyl CpG-binding 
proteins following interacting with GC-rich promoters, our 
results suggested that ISL might enhance WIF1 expression 
through downregulating Sp1 level, which thereafter 
inhibited DNMT1 transcription and recruiting to the 
promoter region of WIF1.
On the other hand, molecular docking analysis 
indicated that ISL might also potentially act as a chemical 
inhibitor of DNMT1. Generally, DNMT inhibitors could 
be divided into nucleoside and non-nucleoside categories 
[69]. The aforementioned 5-azacytidine, decitabine, and 
zebularine belong to the nucleoside analogues, which 
deplete DNMTs by incorporating into DNA and resulting 
in covalent trapping. The nucleoside analogues have 
relatively low specificity and are always characterized 
by substantial cellular and clinical toxicity owing to their 
direct DNA-destroying properties [70]. Compared to 
nucleoside analogues, the non-nucleoside inhibitors appear 
to be less toxic by indirectly blocking DNMT1 activity via 
interfering (through covalent or non-covalent interaction) 
its catalytic site [71–72]. Yoo et al. [73] has applied 
computational methods, and revealed that many DNMT1 
inhibitors could stably dock in the catalytic binding 
site of DNMT1, including (1) natural products, such as 
sinefungin, EGCG, curcumin, parthenolide, and mahanine; 
(2) inhibitors identified from virtual screening, such as 
RG108 and its analogue RG108–1; and (3) approved drugs 
for other indications, such as procaine and procainamide. 
Yoo et al. [73] has also proposed that DNMT1 inhibitors 
commonly share five pharmacophore features at the 
catalytic site of DNMT1. The best-scoring feature is a 
negative charge (N) close to the side chains of Ser1230, 
Gly1231, Lys1535, and Arg1312. The second and third 
favorable features are a donor site (D) that is near the side 
chain of Gly1577 and an acceptor site (A) that is close to 
the side chain of Arg1310 and Arg1312 in the RXR motif. 
The fourth ranked feature is an aromatic ring (R) that 
stabilizes the binding conformations of ligands between 
AdoHcy and Cys1226. The fifth ranked feature is a donor 
site (D) that is near the side chain of Glu1266, which is 
a residue implicated in the mechanism of methylation. 
ISL belongs to the family of non-nucleoside inhibitors. 
In the present investigation, we predicted the binding 
mode of ISL with the catalytic domain of DNMT1 using 
the homology-docking template of the positive DNMT1 
catalytic inhibitor sinefungin, and found that ISL matched 
with the ring (R), donor (D), and acceptor (A) features 
as stated above, which directly interact with Glu1226 
and Arg1312, accompanied by Cys1226 as a surrounding 
amino acid. However, no direct interaction between ISL 
and Cys1226 was observed. The results suggested that 
the inhibitory effects of ISL on DNMT1 activity might 
largely depend on transcriptional regulation. Further study 
is still needed to explore the detailed molecular interaction 
between ISL and DNMT1.
Taken together, our study demonstrated that 
the dietary compound ISL prevents mammary 
carcinogenesis by inhibiting breast cancer stem cells 
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through DNMT1-mediated WIF1 demethylation. Our 
findings not only provide preclinical evidence for 
supporting ISL as a natural chemopreventive agent but 
also shed novel light on the development of WIF1 as an 
epigenetic target for breast cancer prevention.
MATERIALS AND METHODS
Chemicals and reagents
ISL was purchased from Alpha Aesar Company 
(Alfa Aesar, WardHill, MA) with more than 97% purity. 
The stock solution of ISL was prepared in dimethyl 
sulfoxide (DMSO) and kept at − 20°C. Hochest 33342, 
4′, 6-diamidino-2-phenylindole (DAPI), bovine serum 
albumin (BSA) were obtained from Sigma (Sigma, 
St. Louis, MO).
Cell culture
The human breast cancer cell lines MDA-MB-231 
and MCF-7 were obtained from the American Type 
Culture Collection. The cells were cultivated in medium 
(L-15 for MDA-MB-231; 1640 for MCF-7) supplemented 
with 10% FBS and 1% penicillin and streptomycin 
(Gibco Life Technologies, Lofer, Austria) at 37°C in 
a humidified incubator with or without 5% CO2. The 
sorted MDA-MB-231 CSCs were subjected to in vitro 
propagation in DMEM/F12 medium supplemented 
with 1% penicillin and streptomycin, B27 (Invitrogen, 
Carlsbad, CA), 20 ng/ml hEGF (BD Bioscience, Bedford, 
MA), 5 μg/ml insulin and 0.4% BSA for the molecular 
mechanisms study.
Whole mounting assay
3-week-old female mice were genotyped using 
PyMT transgene primers that distinguish between the 
wild type and the PyMT type (Table 1). Mammary glands 
of PYMT mice were excised, and whole-mounts stained 
with carmine alum were analyzed as previously described 
[74]. In particular, the fourth abdominal mammary gland 
was excised during necropsy, spread on glass slides for 
10 min, and fixed in Carnoy’s fixative (6 parts 100% 
ethanol, 3 parts chloroform, and 1 part glacial acetic 
acid) for 4 h. Subsequently, the tissue was washed in 
70% ethanol for 15 min, and the ethanol was changed 
gradually to distilled water, with a final rinse in distilled 
water for 5 min. Staining was carried out overnight in 
carmine alum stain. The tissue was then dehydrated in 
graded alcohol solutions (70, 95, and 100% for 30 min 
each) and was cleared in two changes of xylene (30 min 
each), mounted, and coverslipped using Permount. 
Whole mounts were recorded using a SPOT FLEX® color 
digital camera (Diagnostic Instruments, Inc. Sterling 
Heights, MI).
Immunohistochemistry analysis
Paraffin-embedded tumor sample sections (4 μm in 
thickness) were de-paraffinized in xylene twice for 10 min 
each and rehydrated using a graded series of ethanol. For 
histological observation, H&E staining was used. For 
immunohistochemistry analysis, endogenous peroxidase 
was inactivated by incubating sections in methanol (with 
0.3% hydrogen peroxide) for 30 min at room temperature. 
Antigen retrieval was performed by heating slides in 
sodium-citrate buffer (10 mM, pH 6.0) at 94°C for 10 min. 
The samples were permeabilized in PBS with 0.2% Triton 
X-100 for 15 min, and nonspecific binding was blocked by 
10% normal goat serum for 60 min at room temperature. 
The slides were then incubated with a 1:100 dilution of 
primary antibodies WIF1, DNMT1 and DNMT3b (Cell 
Signaling Technology, Danvers, MA) at 4°C overnight in 
a moist chamber. After three washes with PBS, the slides 
were sequentially incubated with biotinylated secondary 
antibodies for 2 h at room temperature. After three washes 
with PBS, streptavidin-peroxidase conjugate was added 
to the samples and incubated for an additional 30 min 
at room temperature. Finally, the 3, 5-diaminobenzidine 
(DAB) substrate (Dako A/S, Glostrup, Denmark) was used 
for color development, followed by counterstaining with 
Mayer’s hematoxylin. Antigen-positive cells were counted 
in six fields per tumor sample. The results were expressed 
as the average ± SD of tumors per group.
Flow cytometry analysis
Primary mouse mammary cells or breast cancer 
cell lines (MDA-MB-231 and MCF-7) were washed with 
PBS and then harvested with trypsin. The detached cells 
were washed with PBS containing 1% FBS (wash buffer), 
and resuspended in the wash buffer (106 cells/100 μl). 
For SP analysis, cells were stained with Hoechst 33342 
(5 μg/ml) in medium at 37°C for 2 h, and resuspended in 
ice-cold PBS containing 2 μg/ml propidium iodide (PI). 
For ALDEFLUOR assay, the experiment was performed 
using aldehyde dehydrogenase-based cell detection kit 
(Stem Cell Technologies, Grenoble, France) as described 
previously [75]. Briefly, 106 cells were suspended in 
Aldefluor® assay buffer containing ALDH substrate 
(Bodipy-Aminoacetaldehyde) and incubated for 45 min 
at 37°C. As a reference control, the cells were suspended 
in buffer containing Aldefluor® substrate in the presence 
of diethylaminobenzaldehyde (DEAB), a specific ALDH1 
enzyme inhibitor. The brightly fluorescent ALDH1-
expressing cells (ALDH1high) were detected by a 488 nm 
blue laser. For the in vitro stem cell analysis/sorting, 
cells were incubated with combinations of fluorescence-
conjugated monoclonal antibodies obtained from BD 
Biosciences (San Diego, CA, USA) against human 
CD44-FITC and CD24-PE at 4°C in the dark for 40 min 
and then washed once with PBS. FITC- or PE-labeled 
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isotype IgG1 was used as the negative control. For cell 
cycle analysis, cells were fixed with ice-cold 70% ethanol 
at − 20°C overnight. The next day, the cells were washed 
with PBS, stained with 50 mg/mL propidium iodide 
(Sigma, St. Louis, MO), and dissolved in 100 mg/L RNase 
A (Sigma, St. Louis, MO). Flow cytometry analysis was 
conducted with FACSAria SORP (BD Biosciences, San 
Jose, CA), and analyzed by FlowJo or Modifit LT software.
Microarray analysis
Total RNA was harvested from mammary tumor 
tissues of vehicle or ISL-treated MMTV-PyMT mice, 
extracted using TRIzol reagent (Invitrogen, Carlsbad, 
CA), and further purified with RNeasy kits (Qiagen, 
Chatsworth, CA). Microarray analysis was performed 
with the Affymetrix GeneChip® Mouse Gene 2.0 ST 
array (Affymetrix, Santa Clara, CA) by the Centre for 
Genomic Sciences of HKU. Triplicate independent RNA 
preparations of tumors from vehicle and ISL-treated 
groups were compared. The results were analyzed by 
GeneSpring12.6 with normalization of the raw gene 
expression data, quality control checks, and subsequent 
analyses. Genes that changed by at least 2.0-fold between 
groups and with a P-value of less than 0.05 were finally 
defined as target genes.
Real-time PCR analysis
Total RNA from primary mammary tumor tissues or 
MDA-MB-231 CSCs was extracted using TRIzol reagent 
(Invitrogen, Carlsbad, CA), and reverse transcription 
was carried out using a first strand cDNA synthesis kit 
(Roche Diagnostics, IN) according to the manufacturer’s 
instructions. Real-time PCR analysis was performed using 
a SYBR Green kit (Roche Diagnostics, IN) on a Roche 
LightCycler 480 detector. The reactions were incubated in 
a 96-well plate at 95°C for 10 min followed by 40 cycles 
of 95°C for 10 s, 55°C for 30 s and 72°C for 1 min. The 
designed primers were listed in Table 1. The Ct value was 
measured during the exponential amplification phase. 
The relative expression level (defined as fold change) of 
the target genes was given by 2−∆∆Ct and normalized to the 
internal control.
Western blot analysis
To determine the protein concentration, cells were 
lysed in RIPA buffer (Sigma, St. Louis, MO) containing 
a protease inhibitor mixture (Roche Diagnostics, IN). The 
protein concentration was measured with the bicinchoninic 
acid assay (Thermo Fisher Scientific, Bonn, Germany). 
Quantified protein lysates (15 μg) were subjected to 
sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) and resolved on 12% polyacrylamide gels. 
The proteins were then transferred onto a PVDF membrane 
(GE Healthcare, Freiburg, Germany). The membrane 
was probed with primary antibodies, including WIF1, 
β-catenin, P-β-catenin (Ser33/37/Thr41), Akt, P-Akt 
(Ser473), GSK3β, P-GSK3β (Ser9), DNMT1, DNMT3b, 
lamin B and β-actin (Cell Signaling Technology, Danvers, 
MA) at 4°C overnight. After three washes with Tris-
buffered saline with 0.05% Tween-20, the membrane 
was incubated with secondary anti-rabbit or anti-mouse 
antibodies (Cell Signaling Technology, Danvers, MA) for 





















the ECL Advance reagent (GE Healthcare) and quantified 
using Quantity One software.
Immunofluorescence analysis
The untreated and ISL-treated MDA-MB-231 
and MCF-7 breast cancer cells were fixed in 4% 
paraformaldehyde for 10 min and permeabilized with 
0.2% triton X-100. After blocking in 10% goat serum for 
1 h, the slide was incubated with primary WIF1 antibody 
(Santa Cruz, CA) overnight at 4°C, followed by secondary 
fluorescence-labeled antibodies (Santa Cruz, CA) for 2 h 
at room temperature. Finally, the samples were incubated 
with DAPI for nuclear staining and the signal was detected 
with a confocal microscope.
Mammosphere formation assays
The sorted breast CSCs from MDA-MB-231 and 
MCF-7 were plated and cultured in 24-well ultralow 
attachment plates at a density of 1000 cells per well. 
The plating medium for mammosphere formation 
consisted of DMEM/F12 medium supplemented with 
B27, 20 ng/ml hEGF, 5 μg/ml insulin, 0.4% BSA and 
1% penicillin and streptomycin. To examine the effects 
of ISL on the formation of mammospheres, the 3rd day 
mammospheres were treated with varying concentrations 
of ISL. The plating medium was refreshed every 3 days 
in the absence of additional ISL treatment and the 
appearance of primary spheres was evaluated after 5 days. 
To assess the effects of ISL over the secondary and the 
third passage, mammospheres from the previous plating 
were collected and dissociated into single-cell suspensions 
with 0.05% trypsin, filtered using a 40-μm sieve and 
re-plated in ultra-low attachment plates. The number and 
size of the resulting mammospheres were observed with 
no additional treatment. Three independent experiments 
were conducted.
MSP and BGS analysis
MDA-MB-231 and MCF-7 cells were treated with 
or without varying concentrations of ISL for varied time 
intervals. After treatment, the genomic DNA was extracted 
using the Genomic DNA Mini Kit for Cultured Cells 
(Geneaid Biotech Ltd, Sijhih City, Taiwan) according to 
the manufacturer’s instructions. Approximately 0.5 μg 
of genomic DNA was bisulfite-modified using the 
EZ DNA Methylation Kit (Zymo Research, Orange, 
CA). The WIF1 promoter region has been identified 
and described previously [76]. The methylation sites for 
MSP and BGS at WIF1 prompter were also validated 
by the studies of Mazieres et al. [77] and Yang et al. 
[78]. For MSP analysis, bisulfite-treated genomic DNA 
was amplified using either a methylation-specific or an 
unmethylation-specific primer set targeting the WIF1 
promoter region sequences from −488 to −290. The 
designed methylation- and unmethylation-specific primers 
were listed in Table 1. The PCR was carried out under 
the following conditions: one cycle of 95°C for 10 min, 
followed by 35 cycles of denaturing at 94°C for 1 min, 
annealing at 60°C for 50 s and extension at 72°C for 50 s, 
which was followed by the final extension at 72°C for 
10 min. The PCR products were analyzed by 
electrophoresis on a 2% agarose gel and samples were 
visualized with a UV imaging system. For BGS sequencing 
analysis, bisulfite-treated genomic DNA was amplified 
using primers designed to amplify nucleotides from 
−555 to −140 of the WIF1 promoter region. The designed 
primers were listed in Table 1. The PCR was carried out 
under the following conditions: one cycle of 94°C for 
2 min, followed by 35 cycles of denaturing at 94°C for 
15 s, annealing at 55°C for 30 s and extension at 68°C 
for 40 s, which was followed by the final extension at 
72°C for 15 min. The PCR products were cloned into 
the pCRTM4-TOPO® Vector and transformed into 
competent E. coli DH5a using the TOPO® TA cloning® kit 
(Invitrogen, Carlsbad, CA). Positive clones were selected 
for sequencing using M13 primer in the Genomic Centre 
of the University of Hong Kong. The DNA methylation 
analysis was conducted with software BiQ Analyzer [79].
DNMT1 siRNA construction and transfection
The siRNAs targeting DNMT1 or their scrambled 
siRNAs were purchased from Invitrogen (Carlsbad, 
CA, USA) and transfected into breast cancer cells 
MDA-MB-231 using X-tremeGENE siRNA transfection 
reagent (Roche Diagnostics, IN) according to the 
manufacturer’s instructions.
Molecular docking
The LigandFit algorithm in Discovery Studio 2.5 
was used in the molecular docking study. The LigandFit 
algorithm employed a Monte Carlo conformational search 
procedure to generate ligand docking conformations. The 
chemical structure of ISL was drawn by Chemoffice 2002 
(CambridgeSoft, Cambridge, MA). The crystal structure 
of the DNMT1 catalytic structure was obtained from 
the Protein Data Bank (http://www.rcsb.org/pdb/) with 
the ID of 3SWR. The water molecules in DNMT1 were 
removed. For docking purposes, the catalytic site of the 
Cys 1226 domain within the DNMT1 catalytic structure 
was defined as the ligand-binding site and ISL was docked 
into DNMT1 with the correct parameter settings. The 
potentials to form hydrogen bonds and π-π interactions 
within the active site were calculated. Docking with no 
output pose was considered a failure. Accuracy testing 
was performed by calculating the root mean square 
deviation (RMSD) after re-docking the internal ligand 




The data were shown as the mean ± SD. A 
two-tailed Student’s t-test or one-way analysis of variance 
was used to determine the significance of the data between 
groups. Statistical significance was reached when the 
P value < 0.05.
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